Approved for use through 11/30/2020. OMB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`Complete if Known
`Substitute for form 1449/PTO
`
`INFORMATION DISCLOSURE EE
`STATEMENTBY APPLICANT a
`(Use as many sheets as necessary)
`PExaminerName‘(CRUZ KATHRIEN ANN
`Attorney Docket Number
`46682-701.317
`
`16/908 426
`Application Number
`-22-
`Filing Dat
`
`
`.
`
`
`
`[US]
`
`U. S. PATENT DOCUMENTS
`
`Publication Date
`Nameof Patentee or
`Examiner
`Pages, Columns, Lines, Where
`Initials*
`MM-DD-YYYY
`Applicant of Cited Document
`Relevant Passagesor Relevant
`Figures Appear
`
`Document Number
`
`Number-Kind Code? “kw
`
`Examiner
`Initials*
`
`Cit
`No!
`
`Foreign Patent Document
`
`Country Code*Number*Kind Code’(if known)
`
`Publication
`Date
`MM-DD-YYYY
`
`Nameof Patentee or
`Applicant of Cited Document
`
`Pages, Columns, Lines,
`Where Relevant Passages
`Or Relevant Figures Appear
`
`FOREIGN PATENT DOCUMENTS
`
`WO-2016025560-A1
`
`UNIV FLORIDA
`
` Examiner
`
`Date
`
`O1/13/2022
`
`/KATHRIEN A CRUZ/
`
`*EXAMINER: Initial if reference considered, whetherornot citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not
`considered. Include copy of this form with next communication to applicant.
`‘ Applicant’s unique citation designation number (optional).
`; See Kinds Codes of USPTO Patent
`Documents at www.uspto.govor MPEP 901.04. : Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). . For Japanese patent documents, the
`indication of the year of the reign of the Emperor must precede the serial number of the patent document. *kind of document by the appropriate symbols as indicated on the
`document under WIPO Standard ST.16 if possible. Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by
`37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is
`governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application
`form to the USPTO. Timewill vary depending uponthe individual case. Any comments on the amountof time you require to complete this form and/or suggestions for reducing this
`burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED
`FORMS TO THIS ADDRESS. SEND TO: Commissionerfor Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/K.A.c/
`
`

`

`Approved for use through 11/30/2020. OMB 0651-0031
`U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE
`Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unlessit contains a valid OMB control number.
`
`Complete if Known
`Substitute for form 1449/PTO
`Application Number
`16/908 426
`Filing Dat
`-22-
`
`
`INFORMATION DISCLOSURE EE
`STATEMENTBY APPLICANT a
`(Use as many sheets as necessary)
`PExaminerName‘(CRUZ KATHRIEN ANN
`Attorney Docket Number
`46682-701.317
`
`Examiner
`Initials*
`
`Include nameof the author(in CAPITAL LETTERS),title of the article(when appropriate), title of
`the item (book,magazine journal,serial,symposium,catalog,etc.) date,page(s), volume-issue
`number(s),publisher, city and/or country where published.
`
`
`;
`
`Co., Ltd., pp. 134-135 (2009).
`
`
`
`ABAK. Pure technology in a bottle. The history of a technological revolution. LABORATOIRES
`THEA -12 RUE LOUIS BLERIOT -63017 CLERMONT FERRAND -FRANCE Tel. Retrieved
`from the Internet: https://www.laboratoires-thea.com/medias/abak_brochure_eng.pdf (pgs. 1-53)
`(2011-04-18).
`
`Atropine sulfate injection 0.5 mg "Tanabe" Pharmaceutical Interview Form, 2007
`(English/Machine Translation).
`
`
`SASUKIet al. Medicine and dosage regimen in the ophthalmic region, Pharmaceutical Journal
`
`004
`
`U.S. Serial No. 16/785,411 Office Action dated June 28, 2021.
`
`Oo
`
`
`
`Examiner
`Signature
`
`/KATHRIEN A CRUZ/
`
`Date ;
`Considered
`
`01/18/2022
`
`*EXAMINER: Initial if reference considered, whetheror not citation is in conformance with MPEP 609. Drawline through citation if not in conformance and not considered. Include
`copy of this form with next communication to applicant. 1 Applicant’s unique citation designation number(optional). 2 Applicant is to place a check mark hereif English language
`Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public whichis to file (and by the
`USPTOto process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering,
`preparing, and submitting the completed application form to the USPTO. Timewill vary depending uponthe individual case. Any comments on the amountof time you require to
`complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA
`22313-1450. DO NOT SEND FEES OR COMPLETED FORMSTO THIS ADDRESS. SEND TO: Commissionerfor Patents, P.O. Box 1450, Alexandria, VA 22313-1450.
`If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.
`
`ALL REFERENCES CONSIDERED EXCEPT WHERE LINED THROUGH.
`
`/K.A.c/
`
`